A Study to Evaluate the Impact of Pre-procedural Intracoronary Nicorandil Injection to PREVENT ReductioN of DecREased TIMI FLOW in Patients Who Undergoing Percutaneous Coronary Intervention for the Coronary Artery Disease

Exclusion Criteria

• •1. Patients with TIMI ≤ 2 before coronary intervention
• •2. Subjects with known hypersensitivity or contraindications to the following drugs or substances: heparin, aspirin, clopidogrel, ticagrelor, prasugrel, rosuvastatin, ezetimibe, evolocumab, lansoprazole, cobalt chromium, stainless steel nickel And contrast agents (however, even a subject who is hypersensitive to contrast agents can register if they can be controlled by steroids and pheniramine, except for known anaphylaxis.)
• •3. Pregnant women, lactating women, or women of childbearing age who plan to become pregnant during this study
• •4. Subjects who plan to have surgery to stop antiplatelet drugs within 6 months from registration
• •5. Those whose surviving life is expected to be less than 1 year
• •6. Subjects who visited the hospital due to cardiogenic shock and are predicted to have low survival probability based on medical judgment